phosphorylated erbb4 perbb4 y984 Search Results


phosphorylated erbb4 perbb4 y984  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc phosphorylated erbb4 perbb4 y984
Dacomitinib reduces <t>ERBB4</t> phosphorylation in vivo but antagonizes conventional medulloblastoma chemotherapeutics in vitro . (A) SMO mice harboring medulloblastomas were treated with vehicle, dacomitinib (doses indicated) or a combination of dacomitinib and cyclophosphamide (CPA, 150 mg/kg). Tumors were stained for phosphorylated or total ErbB4, stain intensity determined using ImageJ, and the ratio of phosphorylated:total ErbB4 was determined. Shown is mean ± SEM, n = 5 mice per group. Groups were compared using a Student’s t-test (* P < .05). In vitro interactions between dacomitinib and ( B ) 4-hydroperoxycyclophosphamide (4HPC), ( C ) cisplatin and ( D ) vincristine were determined using CompuSyn. Graphs show the combination index (CI) values versus factor affected (Fa) values, where values above or below the dashed line indicate antagonism or synergism, respectively. Mean CI ± standard deviation are shown. Closed circles, open squares and open triangles indicate replicate experiments.
Phosphorylated Erbb4 Perbb4 Y984, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phosphorylated+erbb4+perbb4+y984/Phospho-HER4%2FErbB4+(Tyr984)%2FEGFR+(Tyr978)+Antibody/pmc05916087-81-34-38
Average 93 stars, based on 1 article reviews
phosphorylated erbb4 perbb4 y984 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier
total erbb4  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology total erbb4
Dacomitinib reduces <t>ERBB4</t> phosphorylation in vivo but antagonizes conventional medulloblastoma chemotherapeutics in vitro . (A) SMO mice harboring medulloblastomas were treated with vehicle, dacomitinib (doses indicated) or a combination of dacomitinib and cyclophosphamide (CPA, 150 mg/kg). Tumors were stained for phosphorylated or total ErbB4, stain intensity determined using ImageJ, and the ratio of phosphorylated:total ErbB4 was determined. Shown is mean ± SEM, n = 5 mice per group. Groups were compared using a Student’s t-test (* P < .05). In vitro interactions between dacomitinib and ( B ) 4-hydroperoxycyclophosphamide (4HPC), ( C ) cisplatin and ( D ) vincristine were determined using CompuSyn. Graphs show the combination index (CI) values versus factor affected (Fa) values, where values above or below the dashed line indicate antagonism or synergism, respectively. Mean CI ± standard deviation are shown. Closed circles, open squares and open triangles indicate replicate experiments.
Total Erbb4, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phosphorylated+erbb4+perbb4+y984/ErbB-4+Antibody/pmc05916087-81-43-45
Average 93 stars, based on 1 article reviews
total erbb4 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier
cleaved caspase-3 (cc3  (Becton Dickinson)
90
Becton Dickinson cleaved caspase-3 (cc3
Dacomitinib inhibits EGFR phosphorylation and reduces proliferation in brain tumor xenografts. ( A ) Representative sections of U87vlll.Luc2 glioblastoma, Daoy.Luc2 medulloblastoma and 452.Luc2 pineoblastoma tumors from vehicle- or dacomitinib-treated animals stained for phosphorylated EGFR (Y1173) ( brown ) and counterstained with hematoxylin ( blue ). Scale bar indicates 50 μm. The percentage of tumor cells positive for ( B ) Ki67 or ( C ) cleaved <t>caspase-3</t> <t>(CC3)</t> was determined from U87vIII.Luc2, Daoy.Luc2 and 452.Luc2 xenografts after treatment with vehicle ( white ) or dacomitinib ( grey ). Bars show mean ± SEM. n = 4-7 mice per group. * P < .05.
Cleaved Caspase 3 (Cc3, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phosphorylated+erbb4+perbb4+y984/cleaved+caspase+3/pmc05916087-81-22-25
Average 90 stars, based on 1 article reviews
cleaved caspase-3 (cc3 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Dacomitinib reduces ERBB4 phosphorylation in vivo but antagonizes conventional medulloblastoma chemotherapeutics in vitro . (A) SMO mice harboring medulloblastomas were treated with vehicle, dacomitinib (doses indicated) or a combination of dacomitinib and cyclophosphamide (CPA, 150 mg/kg). Tumors were stained for phosphorylated or total ErbB4, stain intensity determined using ImageJ, and the ratio of phosphorylated:total ErbB4 was determined. Shown is mean ± SEM, n = 5 mice per group. Groups were compared using a Student’s t-test (* P < .05). In vitro interactions between dacomitinib and ( B ) 4-hydroperoxycyclophosphamide (4HPC), ( C ) cisplatin and ( D ) vincristine were determined using CompuSyn. Graphs show the combination index (CI) values versus factor affected (Fa) values, where values above or below the dashed line indicate antagonism or synergism, respectively. Mean CI ± standard deviation are shown. Closed circles, open squares and open triangles indicate replicate experiments.

Journal: Neoplasia (New York, N.Y.)

Article Title: A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors

doi: 10.1016/j.neo.2018.02.004

Figure Lengend Snippet: Dacomitinib reduces ERBB4 phosphorylation in vivo but antagonizes conventional medulloblastoma chemotherapeutics in vitro . (A) SMO mice harboring medulloblastomas were treated with vehicle, dacomitinib (doses indicated) or a combination of dacomitinib and cyclophosphamide (CPA, 150 mg/kg). Tumors were stained for phosphorylated or total ErbB4, stain intensity determined using ImageJ, and the ratio of phosphorylated:total ErbB4 was determined. Shown is mean ± SEM, n = 5 mice per group. Groups were compared using a Student’s t-test (* P < .05). In vitro interactions between dacomitinib and ( B ) 4-hydroperoxycyclophosphamide (4HPC), ( C ) cisplatin and ( D ) vincristine were determined using CompuSyn. Graphs show the combination index (CI) values versus factor affected (Fa) values, where values above or below the dashed line indicate antagonism or synergism, respectively. Mean CI ± standard deviation are shown. Closed circles, open squares and open triangles indicate replicate experiments.

Article Snippet: Tissue sections (5 μm) underwent microwave antigen retrieval in a citrate buffer before immunostaining with the following antibodies: Ki-67 (Leica #NCL-Ki67p, 1:5000), cleaved caspase-3 (CC3) (BD #559565, 1:500), p-EGFR Y1173 (Cell Signaling #4407, 1:250), phosphorylated ErbB4 (pErbB4) Y984 (Cell Signaling #3790, 1:50), or total ErbB4 (Santa Cruz #SC-283, 1:200).

Techniques: Phospho-proteomics, In Vivo, In Vitro, Staining, Standard Deviation

Dacomitinib reduces ERBB4 phosphorylation in vivo but antagonizes conventional medulloblastoma chemotherapeutics in vitro . (A) SMO mice harboring medulloblastomas were treated with vehicle, dacomitinib (doses indicated) or a combination of dacomitinib and cyclophosphamide (CPA, 150 mg/kg). Tumors were stained for phosphorylated or total ErbB4, stain intensity determined using ImageJ, and the ratio of phosphorylated:total ErbB4 was determined. Shown is mean ± SEM, n = 5 mice per group. Groups were compared using a Student’s t-test (* P < .05). In vitro interactions between dacomitinib and ( B ) 4-hydroperoxycyclophosphamide (4HPC), ( C ) cisplatin and ( D ) vincristine were determined using CompuSyn. Graphs show the combination index (CI) values versus factor affected (Fa) values, where values above or below the dashed line indicate antagonism or synergism, respectively. Mean CI ± standard deviation are shown. Closed circles, open squares and open triangles indicate replicate experiments.

Journal: Neoplasia (New York, N.Y.)

Article Title: A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors

doi: 10.1016/j.neo.2018.02.004

Figure Lengend Snippet: Dacomitinib reduces ERBB4 phosphorylation in vivo but antagonizes conventional medulloblastoma chemotherapeutics in vitro . (A) SMO mice harboring medulloblastomas were treated with vehicle, dacomitinib (doses indicated) or a combination of dacomitinib and cyclophosphamide (CPA, 150 mg/kg). Tumors were stained for phosphorylated or total ErbB4, stain intensity determined using ImageJ, and the ratio of phosphorylated:total ErbB4 was determined. Shown is mean ± SEM, n = 5 mice per group. Groups were compared using a Student’s t-test (* P < .05). In vitro interactions between dacomitinib and ( B ) 4-hydroperoxycyclophosphamide (4HPC), ( C ) cisplatin and ( D ) vincristine were determined using CompuSyn. Graphs show the combination index (CI) values versus factor affected (Fa) values, where values above or below the dashed line indicate antagonism or synergism, respectively. Mean CI ± standard deviation are shown. Closed circles, open squares and open triangles indicate replicate experiments.

Article Snippet: Tissue sections (5 μm) underwent microwave antigen retrieval in a citrate buffer before immunostaining with the following antibodies: Ki-67 (Leica #NCL-Ki67p, 1:5000), cleaved caspase-3 (CC3) (BD #559565, 1:500), p-EGFR Y1173 (Cell Signaling #4407, 1:250), phosphorylated ErbB4 (pErbB4) Y984 (Cell Signaling #3790, 1:50), or total ErbB4 (Santa Cruz #SC-283, 1:200).

Techniques: In Vivo, In Vitro, Staining, Standard Deviation

Dacomitinib inhibits EGFR phosphorylation and reduces proliferation in brain tumor xenografts. ( A ) Representative sections of U87vlll.Luc2 glioblastoma, Daoy.Luc2 medulloblastoma and 452.Luc2 pineoblastoma tumors from vehicle- or dacomitinib-treated animals stained for phosphorylated EGFR (Y1173) ( brown ) and counterstained with hematoxylin ( blue ). Scale bar indicates 50 μm. The percentage of tumor cells positive for ( B ) Ki67 or ( C ) cleaved caspase-3 (CC3) was determined from U87vIII.Luc2, Daoy.Luc2 and 452.Luc2 xenografts after treatment with vehicle ( white ) or dacomitinib ( grey ). Bars show mean ± SEM. n = 4-7 mice per group. * P < .05.

Journal: Neoplasia (New York, N.Y.)

Article Title: A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors

doi: 10.1016/j.neo.2018.02.004

Figure Lengend Snippet: Dacomitinib inhibits EGFR phosphorylation and reduces proliferation in brain tumor xenografts. ( A ) Representative sections of U87vlll.Luc2 glioblastoma, Daoy.Luc2 medulloblastoma and 452.Luc2 pineoblastoma tumors from vehicle- or dacomitinib-treated animals stained for phosphorylated EGFR (Y1173) ( brown ) and counterstained with hematoxylin ( blue ). Scale bar indicates 50 μm. The percentage of tumor cells positive for ( B ) Ki67 or ( C ) cleaved caspase-3 (CC3) was determined from U87vIII.Luc2, Daoy.Luc2 and 452.Luc2 xenografts after treatment with vehicle ( white ) or dacomitinib ( grey ). Bars show mean ± SEM. n = 4-7 mice per group. * P < .05.

Article Snippet: Tissue sections (5 μm) underwent microwave antigen retrieval in a citrate buffer before immunostaining with the following antibodies: Ki-67 (Leica #NCL-Ki67p, 1:5000), cleaved caspase-3 (CC3) (BD #559565, 1:500), p-EGFR Y1173 (Cell Signaling #4407, 1:250), phosphorylated ErbB4 (pErbB4) Y984 (Cell Signaling #3790, 1:50), or total ErbB4 (Santa Cruz #SC-283, 1:200).

Techniques: Staining